218 related articles for article (PubMed ID: 16648135)
1. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.
Gallo SA; Wang W; Rawat SS; Jung G; Waring AJ; Cole AM; Lu H; Yan X; Daly NL; Craik DJ; Jiang S; Lehrer RI; Blumenthal R
J Biol Chem; 2006 Jul; 281(27):18787-92. PubMed ID: 16648135
[TBL] [Abstract][Full Text] [Related]
2. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
Zhao C; Princiotto AM; Nguyen HT; Zou S; Zhao ML; Zhang S; Herschhorn A; Farrell M; Pahil K; Melillo B; Sambasivarao SV; Abrams C; Smith AB; Madani N; Sodroski J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391272
[TBL] [Abstract][Full Text] [Related]
3. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
Keller PW; Morrison O; Vassell R; Weiss CD
J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
[TBL] [Abstract][Full Text] [Related]
5. The theta-defensin, retrocyclin, inhibits HIV-1 entry.
Münk C; Wei G; Yang OO; Waring AJ; Wang W; Hong T; Lehrer RI; Landau NR; Cole AM
AIDS Res Hum Retroviruses; 2003 Oct; 19(10):875-81. PubMed ID: 14585219
[TBL] [Abstract][Full Text] [Related]
6. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
Miyauchi K; Kozlov MM; Melikyan GB
PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41.
Cole AL; Yang OO; Warren AD; Waring AJ; Lehrer RI; Cole AM
J Immunol; 2006 Jun; 176(11):6900-5. PubMed ID: 16709850
[TBL] [Abstract][Full Text] [Related]
8. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015).
Li W; Lu L; Li W; Jiang S
Expert Opin Ther Pat; 2017 Jun; 27(6):707-719. PubMed ID: 28076686
[TBL] [Abstract][Full Text] [Related]
9. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41.
Fuhrman CA; Warren AD; Waring AJ; Dutz SM; Sharma S; Lehrer RI; Cole AL; Cole AM
FEBS J; 2007 Dec; 274(24):6477-87. PubMed ID: 18028423
[TBL] [Abstract][Full Text] [Related]
10. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
11. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
[TBL] [Abstract][Full Text] [Related]
12. Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.
De Feo CJ; Wang W; Hsieh ML; Zhuang M; Vassell R; Weiss CD
Retrovirology; 2014 Oct; 11():86. PubMed ID: 25274545
[TBL] [Abstract][Full Text] [Related]
13. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
14. The potent human immunodeficiency virus type 1 (HIV-1) entry inhibitor HR212 blocks formation of the envelope glycoprotein gp41 six-helix bundle.
Ouyang W; An T; Guo D; Wu S; Tien P
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):613-20. PubMed ID: 23308369
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 gp41: mediator of fusion and target for inhibition.
Weiss CD
AIDS Rev; 2003; 5(4):214-21. PubMed ID: 15012000
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.
Gallo SA; Puri A; Blumenthal R
Biochemistry; 2001 Oct; 40(41):12231-6. PubMed ID: 11591141
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells.
Denizot M; Varbanov M; Espert L; Robert-Hebmann V; Sagnier S; Garcia E; Curriu M; Mamoun R; Blanco J; Biard-Piechaczyk M
Autophagy; 2008 Nov; 4(8):998-1008. PubMed ID: 18818518
[TBL] [Abstract][Full Text] [Related]
19. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
Platt EJ; Durnin JP; Kabat D
J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
[TBL] [Abstract][Full Text] [Related]
20. Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates.
Golding H; Zaitseva M; de Rosny E; King LR; Manischewitz J; Sidorov I; Gorny MK; Zolla-Pazner S; Dimitrov DS; Weiss CD
J Virol; 2002 Jul; 76(13):6780-90. PubMed ID: 12050391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
